FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2789969141> ?p ?o ?g. }

• W2789969141 endingPage "868" @default.
• W2789969141 startingPage "860" @default.
• W2789969141 abstract "Background C-Met, which is frequently activated in multiple cancers, has been implicated in tumor formation, progression, metastasis, angiogenesis, and resistance to multiple therapies. MK-8033 is a small-molecule inhibitor of c-Met that binds preferentially to the activated conformation, and has demonstrated anti-tumor activity in preclinical models. This first-in-human trial was performed to establish the safety and maximum tolerated dose (MTD), as well as preliminary pharmacokinetics (PK) and clinical activity. Methods Forty-seven patients were enrolled in three parts. The primary objective of Parts A and B was safety, whereas Part C evaluated the effect of proton-pump inhibitors on MK-8033 absorption. Dose escalation used an accelerated continual reassessment method, and dose-limiting toxicities (DLTs) were any treatment-related, first course non-hematologic grade ≥ 3 toxicity (except alopecia or inadequately treated nausea/vomiting/diarrhea), grade 4 hematologic toxicity (except grade 3 neutropenic fever and thrombocytopenia), or toxicity where treatment is held >3 weeks. Results Forty-six patients were treated across nine dose levels, and the MTD was 750 mg twice daily. DLTs were fatigue, nausea, vomiting, transaminitis, and hypokalemia. Most frequent toxicities were fatigue (28.3%), nausea (21.7%), and alopecia (19.6%), predominately grade ≤ 2. One patient with endometriod adenocarcinoma achieved a partial response and eight had stable disease. Median progression-free survival (PFS) was 57 days. Strikingly, the PFS for the one responder was 846 days. PK results showed that proton-pump inhibitors have no effect on MK-8033 absorption. Conclusion MK-8033 was well tolerated with no significant toxicity issues, albeit with limited clinical activity. Unfortunately, the company decided to discontinue further clinical development of MK-8033." @default.
• W2789969141 created "2018-03-29" @default.
• W2789969141 creator A5011642439 @default.
• W2789969141 creator A5022436659 @default.
• W2789969141 creator A5039492614 @default.
• W2789969141 creator A5050740210 @default.
• W2789969141 creator A5075392197 @default.
• W2789969141 creator A5087055974 @default.
• W2789969141 date "2018-01-29" @default.
• W2789969141 modified "2023-09-23" @default.
• W2789969141 title "First-in-human phase I dose escalation study of MK-8033 in patients with advanced solid tumors" @default.
• W2789969141 cites W117902596 @default.
• W2789969141 cites W1508955841 @default.
• W2789969141 cites W1836112980 @default.
• W2789969141 cites W1976331950 @default.
• W2789969141 cites W1977301198 @default.
• W2789969141 cites W1977436845 @default.
• W2789969141 cites W1979055605 @default.
• W2789969141 cites W1979491122 @default.
• W2789969141 cites W1985995844 @default.
• W2789969141 cites W1989535705 @default.
• W2789969141 cites W1999740664 @default.
• W2789969141 cites W2013878853 @default.
• W2789969141 cites W2018672261 @default.
• W2789969141 cites W2033161279 @default.
• W2789969141 cites W2041488627 @default.
• W2789969141 cites W2051947815 @default.
• W2789969141 cites W2054042846 @default.
• W2789969141 cites W2067288984 @default.
• W2789969141 cites W2075081031 @default.
• W2789969141 cites W2096844786 @default.
• W2789969141 cites W2097574458 @default.
• W2789969141 cites W2105138727 @default.
• W2789969141 cites W2120795894 @default.
• W2789969141 cites W2135517619 @default.
• W2789969141 cites W2136146667 @default.
• W2789969141 cites W2139073495 @default.
• W2789969141 cites W2143272762 @default.
• W2789969141 cites W2160725767 @default.
• W2789969141 cites W2167228337 @default.
• W2789969141 cites W2218313846 @default.
• W2789969141 cites W2237254160 @default.
• W2789969141 cites W2329648702 @default.
• W2789969141 cites W2586401019 @default.
• W2789969141 cites W2787353230 @default.
• W2789969141 cites W4245967957 @default.
• W2789969141 doi "https://doi.org/10.1007/s10637-018-0567-z" @default.
• W2789969141 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7507839" @default.
• W2789969141 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29376210" @default.
• W2789969141 hasPublicationYear "2018" @default.
• W2789969141 type Work @default.
• W2789969141 sameAs 2789969141 @default.
• W2789969141 citedByCount "4" @default.
• W2789969141 countsByYear W27899691412020 @default.
• W2789969141 countsByYear W27899691412021 @default.
• W2789969141 countsByYear W27899691412022 @default.
• W2789969141 countsByYear W27899691412023 @default.
• W2789969141 crossrefType "journal-article" @default.
• W2789969141 hasAuthorship W2789969141A5011642439 @default.
• W2789969141 hasAuthorship W2789969141A5022436659 @default.
• W2789969141 hasAuthorship W2789969141A5039492614 @default.
• W2789969141 hasAuthorship W2789969141A5050740210 @default.
• W2789969141 hasAuthorship W2789969141A5075392197 @default.
• W2789969141 hasAuthorship W2789969141A5087055974 @default.
• W2789969141 hasBestOaLocation W27899691412 @default.
• W2789969141 hasConcept C112705442 @default.
• W2789969141 hasConcept C126322002 @default.
• W2789969141 hasConcept C143998085 @default.
• W2789969141 hasConcept C2777063308 @default.
• W2789969141 hasConcept C2780580376 @default.
• W2789969141 hasConcept C2780852908 @default.
• W2789969141 hasConcept C29730261 @default.
• W2789969141 hasConcept C31760486 @default.
• W2789969141 hasConcept C71924100 @default.
• W2789969141 hasConcept C90924648 @default.
• W2789969141 hasConcept C98274493 @default.
• W2789969141 hasConceptScore W2789969141C112705442 @default.
• W2789969141 hasConceptScore W2789969141C126322002 @default.
• W2789969141 hasConceptScore W2789969141C143998085 @default.
• W2789969141 hasConceptScore W2789969141C2777063308 @default.
• W2789969141 hasConceptScore W2789969141C2780580376 @default.
• W2789969141 hasConceptScore W2789969141C2780852908 @default.
• W2789969141 hasConceptScore W2789969141C29730261 @default.
• W2789969141 hasConceptScore W2789969141C31760486 @default.
• W2789969141 hasConceptScore W2789969141C71924100 @default.
• W2789969141 hasConceptScore W2789969141C90924648 @default.
• W2789969141 hasConceptScore W2789969141C98274493 @default.
• W2789969141 hasFunder F4320307776 @default.
• W2789969141 hasIssue "5" @default.
• W2789969141 hasLocation W27899691411 @default.
• W2789969141 hasLocation W27899691412 @default.
• W2789969141 hasOpenAccess W2789969141 @default.
• W2789969141 hasPrimaryLocation W27899691411 @default.
• W2789969141 hasRelatedWork W1481779217 @default.
• W2789969141 hasRelatedWork W1963629383 @default.
• W2789969141 hasRelatedWork W1998138487 @default.
• W2789969141 hasRelatedWork W2006876985 @default.
• W2789969141 hasRelatedWork W2018958796 @default.

• next